Last reviewed · How we verify
Standard dose lamotrigine
Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.
Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability. Used for Epilepsy (adjunctive and monotherapy), Bipolar disorder maintenance treatment, Lennox-Gastaut syndrome.
At a glance
| Generic name | Standard dose lamotrigine |
|---|---|
| Also known as | Standard lamotrigine |
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Drug class | Anticonvulsant / Antiepileptic drug |
| Target | Voltage-gated sodium channels; glutamate release inhibition |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Lamotrigine stabilizes neuronal membranes by blocking sodium channels in a use-dependent manner, which prevents repetitive neuronal firing. It also inhibits the release of glutamate, an excitatory neurotransmitter, through effects on calcium channels. These combined actions reduce abnormal electrical activity in the brain.
Approved indications
- Epilepsy (adjunctive and monotherapy)
- Bipolar disorder maintenance treatment
- Lennox-Gastaut syndrome
Common side effects
- Rash (including Stevens-Johnson syndrome risk)
- Dizziness
- Ataxia
- Somnolence
- Headache
- Diplopia
- Nausea
Key clinical trials
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- IV Ketamine Vs. in Esketamine for MDD TRD
- Precision Medicine in the Treatment of Epilepsy
- Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study (PHASE4)
- Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed Tablets in China (PHASE1)
- Bioequivalence and Food Effect of 250mg of Lamotrigine XR (PHASE1)
- Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: